TG Therapeutics News and Activities
Presence
TG Therapeutics develops and sells medicines for autoimmune and blood-related diseases. Its main products and research programs serve patients, hospitals, and specialist doctors in the United States.
TG Therapeutics products and services overview:
- Autoimmune medicines
- Blood disorder therapies
- Biologic treatments
- Specialty pharmaceuticals
- Clinical research
Revenue: ~$309 million
Employees: 350
Headquarters: Morrisville, United States (USA)
TG Therapeutics is one of the...
TG Therapeutics is a company listed under the stock ticker TGTX (US).
Executives
View the org chart displaying its 18 main executives
Most searched biographies at TG Therapeutics
- Michael Weiss, Executive Chairman, President and Chief Executive O...
- Laurence Charney, Director
- Kenneth Hoberman, Director
Popular executive movements at TG Therapeutics
- Chris Johnson, Associate Director, Quality Operations, has left the company (posted on November 28 2025).
Create your alert
to follow the executive moves at TG Therapeutics.
Pharmaceuticals
TG Therapeutics has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by TG Therapeutics
- TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology | TG Therapeutics, Inc.
- TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting | TG Therapeutics, Inc.
- TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS | TG Therapeutics, Inc.
- TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting | TG Therapeutics, Inc.
- TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference | TG Therapeutics, Inc.
- TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference | TG Therapeutics, Inc.
- TG Therapeutics Announces Fast Track Designation Granted by the FDA to Ublituximab in Combination with Umbralisib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia | TG Therapeutics, Inc.
- RSS News Feeds | TG Therapeutics, Inc.
- TG Therapeutics to Present at Upcoming Investor Conferences | TG Therapeutics, Inc.
- TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma | TG Therapeutics, Inc.
- View more press releases Close
Social media about TG Therapeutics
- TG Therapeutics on Wikipedia, Google News & Yahoo Finance
- TG Therapeutics on LinkedIn, X (Twitter) & YouTube
